

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.5. Antitrypanosomal medicines](#) > [6.5.5.1. African trypanosomiasis](#) > [6.5.5.1.2. Medicines for the treatment of 2nd stage African trypanosomiasis](#)

		EMLc	ATC codes: <a href="#">P01CC01</a>
Indication	Gambiense trypanosomiasis	ICD11 code: <a href="#">1F51.0</a>	
INN	Nifurtimox		
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Additional notes	Only to be used in combination with eflornithine, for the treatment of <i>Trypanosoma brucei</i> gambiense infection.		
Formulations	Oral > Solid > tablet: 30 mg (scored) ; 120 mg (scored)		
EML status history	First added in 2009 ( <a href="#">TRS 958</a> ) Changed in 2013 ( <a href="#">TRS 985</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Nifurtimox</a> 		
DrugBank	<a href="#">Nifurtimox</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of nifurtimox 250 mg tablets from the EML and EMLc, and the addition of nifurtimox 30 mg tablets to the EMLc (Section 6.5.5.1).

